<<Be Very Careful...VERY CAREFUL!>>
I reviewed the 504 offer as well, and have to agree...
However, their drug does look promising - does CRS have any other agents in their pipeline? It's hard to base an investment on one product, no matter how good it looks ( I should be one to talk... ).
Dr. R.W. Urban's publications and selected articles re: ImuVert that I could find in my literature search - apparently there is a phase II trial ongoing in pts with brain tumors (astrocytoma), but nothing published. Basically, the Phase I clinical trials showed some minor toxicity and some response to some pretty nasty cancers. I assume that NPP5 and/or NPP5A refer to the drug "ImuVert," but that isn't clear from the 504.
J Clin Oncol 1993 Sep;11(9):1746-1750 (Phase I, 15 pts, brain tumor)
Cancer Immunol Immunother 1992;35(5):331-334 (Phase I, 39 pts, various tumors)
Mol Biother 1989;1(3):145-151 (in vitro experiment)
Mol Biother 1989;1(6):323-327 (in vitro exp't)
Cancer Res 1980 May;40(5):1501-1505 (mice)
IMHO, the concept of immunotherapy, trying to rev up the immune system to "reject" any tumor, is attractive, but has a long way to go. Hopefully, this particular agent will be better than the rest. LOL.
ACC |
